Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern

The rapid development, approval, and production of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in less than 1 year after the first reports of a new infectious disease was a real game changer, providing 80%–90% efficacy in preventing severe etiopathologies of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarze, Mandy, Krizsan, Andor, Brakel, Alexandra, Pohl, Fabian, Volke, Daniela, Hoffmann, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242094/
https://www.ncbi.nlm.nih.gov/pubmed/35784285
http://dx.doi.org/10.3389/fimmu.2022.915034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242094/
https://www.ncbi.nlm.nih.gov/pubmed/35784285
http://dx.doi.org/10.3389/fimmu.2022.915034

Ejemplares similares